Thermo Fisher Scientific Inc. $TMO Shares Acquired by EP Wealth Advisors LLC

Key Points

• EP Wealth Advisors LLC increased its holdings in Thermo Fisher Scientific by 10.7% in the first quarter, bringing its total shares to 17,562 valued at $8.7 million.
• Thermo Fisher Scientific's most recent earnings report showed an EPS of $5.36, beating estimates, with revenue reaching $10.86 billion for the quarter.
• The company announced a quarterly dividend of $0.43 per share, with a payout ratio of 9.95%, set to be paid on October 15th.

EP Wealth Advisors LLC raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 10.7% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 17,562 shares of the medical research company's stock after purchasing an additional 1,704 shares during the period. EP Wealth Advisors LLC's holdings in Thermo Fisher Scientific were worth $8,739,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of TMO. GAMMA Investing LLC boosted its stake in shares of Thermo Fisher Scientific by 60,610.9% in the first quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock worth $1,203,859,000 after acquiring an additional 2,415,346 shares during the period. Nuveen LLC bought a new position in shares of Thermo Fisher Scientific in the first quarter worth about $532,360,000. Farallon Capital Management LLC boosted its stake in shares of Thermo Fisher Scientific by 73.8% in the fourth quarter. Farallon Capital Management LLC now owns 1,233,256 shares of the medical research company's stock worth $641,577,000 after acquiring an additional 523,800 shares during the period. Sarasin & Partners LLP bought a new position in shares of Thermo Fisher Scientific in the first quarter worth about $242,991,000. Finally, Two Sigma Advisers LP boosted its stake in shares of Thermo Fisher Scientific by 81.6% in the fourth quarter. Two Sigma Advisers LP now owns 933,200 shares of the medical research company's stock worth $485,479,000 after acquiring an additional 419,200 shares during the period. Institutional investors own 89.23% of the company's stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 29,666 shares of company stock valued at $13,982,763. 0.33% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts recently commented on TMO shares. Evercore ISI dropped their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Wells Fargo & Company lowered their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price for the company in a research note on Friday, July 11th. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Saturday, August 30th. Finally, Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the company an "outperform" rating in a research note on Tuesday. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and an average target price of $589.38.

Thermo Fisher Scientific Stock Up 0.6%

Shares of Thermo Fisher Scientific stock traded up $2.71 during trading hours on Friday, reaching $492.20. 1,442,575 shares of the company were exchanged, compared to its average volume of 1,624,930. The firm has a market cap of $185.86 billion, a PE ratio of 28.47, a PEG ratio of 2.61 and a beta of 0.75. The stock's fifty day moving average is $460.72 and its 200 day moving average is $453.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.Thermo Fisher Scientific's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.